Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue:
Total revenue	$ 24,822	$ 23,647
Operating costs and expenses:
Cost of goods sold	5,315	5,756
Research and development	107,253	95,604
General and administrative	27,339	31,679
Restructuring, impairment and other costs of terminated program	1,475	0
Total operating costs and expenses	141,382	133,039
Loss from operations	(116,560)	(109,392)
Non-operating income (expense):
Change in fair value of development derivative liability	33,427	(1,599)
Non-cash interest expense on liabilities related to the sales of future royalties	(7,529)	(13,296)
Interest income and other income (expense), net	395	1,412
Total non-operating income (expense), net	26,293	(13,483)
Loss before provision for income taxes	(90,267)	(122,875)
Provision for income taxes	126	92
Net loss	$ (90,393)	$ (122,967)
Basic net loss per share (in dollars per share)	$ (0.49)	$ (0.68)
Diluted net loss per share (in dollars per share)	$ (0.49)	$ (0.68)
Weighted average shares outstanding used in computing basic net loss per share (in shares)	185,848	181,370
Weighted average shares outstanding used in computing diluted net loss per share (in shares)	185,848	181,370
Product sales
Revenue:
Total revenue	$ 5,688	$ 4,795
Non-cash royalty revenue related to the sales of future royalties
Revenue:
Total revenue	17,561	18,798
License, collaboration and other revenue
Revenue:
Total revenue	$ 1,573	$ 54